Department of Spine Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Foot and Ankle Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Traumatic Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Spine Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Spine Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Spine Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Spine Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Spine Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Spine Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Foot and Ankle Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Traumatic Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Spine Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Spine Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Spine Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Spine Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Department of Spine Surgery, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China fimmu.com
Mechanical stress promotes human ligamentum flavum cells (LFCs) to synthesize multitype collagens, leading to ligamentum flavum hypertrophy (LFH). However, the mechanism of mechanical stress in the formation of collagen remains unclear. Therefore, we investigated the relationship between mechanical stress and collagen synthesis in the present study. First, LFCs were isolated from 9 patients and cultured with or without mechanical stress exposure for different times. IGF-1, collagen I (col-I), and collagen III (col-III) protein and mRNA levels were then detected via ELISA and qPCR, respectively. Moreover, the activation of pIGF-1R, pAKT, and pS6 was examined by Western blot analysis. To further explore the underlying mechanism, an IGF-1 neutralizing antibody, NVP-AEW541, and rapamycin were used. IGF-1, col-I, and col-III were significantly increased in stressed LFCs compared to nonstressed LFCs. In addition, the activation of pIGF-1R, pAKT, and pS6 was obviously enhanced in stressed LFCs. Interestingly, col-I protein, col-I mRNA, col-III protein, col-III mRNA, and IGF-1 protein, but not IGF-1 mRNA, were inhibited by IGF-1 neutralizing antibody. In addition, col-I and col-III protein and mRNA, but not IGF-1, were inhibited by both NVP-AEW541 and rapamycin. Moreover, the activation of pIGF-1R, pAKT, and pS6 was reduced by the IGF-1 neutralizing antibody and NVP-AEW541, and the activation of pS6 was reduced by rapamycin. In summary, these results suggested that mechanical stress promotes LFCs to produce IGF-1, which facilitates col-I and col-III synthesis via the IGF-1R/AKT/mTORC1 signaling pathway.
1. Introduction
Currently, an increasing number of elderly individuals have lumbar spinal stenosis (LSS) [1, 2]. The clinical symptoms of LSS include lower limb numbness with pain, low back pain, and claudication [3]. LSS causes tremendous discomfort for patients, and LSS is often caused by ligamentum flavum hypertrophy (LFH) [4, 5]. Previous studies [6–9] have shown that mechanical stress promotes collagen I (col-I) and collagen III (col-III) synthesis which contributes to LFH. However, the exact mechanisms remain unclear.
According to a previous study [10], IGF-1 is important for anabolism and stimulates the IGF-1R/AKT/mTORC1 signaling pathway, resulting in muscle or bone formation [11–13]. Moreover, increased IGF-1 promotes hypertrophy of various tissues [14–17], and mechanical stress plays a vital role in IGF-1 formation [18, 19]. We have previously reported that [20] exogenous IGF-1 promotes col-I and col-III synthesis in LFCs, which are fibrous connective tissue stem cells. However, in LFH, the relationship of mechanical stress and IGF-1 has not been sufficiently studied.
In the present study, we hypothesized that mechanical stress plays a pivotal role in IGF-1 synthesis. In addition, IGF-1 may promote col-I and col-III synthesis by the IGF-1R/AKT/mTORC1 signaling pathway. To test these hypotheses, col-I and col-III as the important indicator of LFH were detected, and related marker activation of the IGF-1R/AKT/mTORC1 signaling pathway was examined. In addition, the relationship of mechanical stress and IGF-1 in LFH as well as the potential mechanism involved was investigated.
2. Materials and Methods
2.1. LFC Cultivation and Identification
First, nonthickened ligamentum flavum (LF) samples were aseptically obtained from 9 lumbar surgery patients (5 males and 4 females with an average age of 47.2 years). The LF samples were washed with physiological saline 3 times before being minced into 0.5 mm3 pieces. The LF samples were then digested with 0.2% collagenase-I for 1.5 h at 37°C and washed 2 times with PBS. The LF samples were centrifuged 3 times at 1000 r/min for 5 min before being placed in cell culture plates with DMEM containing 20% fetal bovine serum (FBS). Subsequently, The LF samples were incubated, and the medium was changed every 3 days. Approximately one week later, LFCs migrated out from the LF samples. When the LFCs reached 80% confluence, they were passaged 1 : 2. Moreover, some of the LFCs were cryopreserved in media (10%DMSO + 20%FBS + 70%DMEM) at -80°C. LFC morphology was inspected, and the expression of vimentin and col-I in LFCs was detected by immunostaining [21].
2.2. Mechanical Stress Application
Experiments were performed with LFCs from each individual patient. The LFCs were grouped into experimental and control groups, and they were cultured in BioFlex I 6-well plates at 1 × 105 cells per well. After LFCs reached 80% confluence, they were subjected to serum starvation (DMEM with 0.2% FBS) for 12 h. The experimental groups were subjected to cycles of relaxation for 10 s and 20% elongation for 10 s by a tension system (FX5K, Flexcell International Corporation, USA) [22–25] for 6 h, 12 h, and 24 h. Control groups were cultured in the same environment without mechanical stress.
2.3. IGF-1 Neutralizing Antibody Treatment
LFCs were grouped into the following 3 groups: nonstress group, stress group, and stress+IGF-1 neutralizing antibody (10 μg/ml, Abcam, Cambridge, UK) group. LFCs in the stress group and the stress+IGF-1 neutralizing antibody group were subjected to cycles of relaxation for 10 s and 20% elongation for 10 s by the tension system for 24 h, and LFCs in the nonstress group were not subjected to mechanical stress. IGF-1, col-I and col-III protein, and mRNA levels were detected by ELISA and RT-qPCR, respectively, in each group. In addition, the activation of pIGF-1R, pAKT, and pS6 in each group was evaluated by Western blot analysis.
2.4. NVP-AEW541 Treatment
LFCs were grouped into the following 3 groups: nonstress group, stress group, and stress+100 ng/ml NVP-AEW541 (a specific inhibitor of IGF-1R, dissolved in DMSO, MedChem Express, Monmouth Junction, NJ) group. LFCs in the stress group and the stress+100 ng/ml NVP-AEW541 group were subjected to cycles of relaxation for 10 s and 20% elongation for 10 s by the tension system for 24 h, and LFCs in the nonstress group were not subjected to mechanical stress. IGF-1, col-I and col-III protein, and mRNA levels were detected by ELISA and RT-qPCR, respectively, in each group. Moreover, the activation of pIGF-1R, pAKT, and pS6 in each group was evaluated by Western blot analysis.
2.5. Rapamycin Treatment
LFCs were grouped into the following 3 groups: nonstress group, stress group, and stress+10 ng/ml rapamycin (a specific inhibitor of mTORC1, dissolved in DMSO, Alexis Biochemicals, Lausen, Switzerland) group. LFCs in the stress group and the stress+10 ng/ml rapamycin group were subjected to cycles of relaxation for 10 s and 20% elongation for 10 s by the tension system for 24 h, and LFCs in the nonstress group were not subjected to mechanical stress. IGF-1, col-I and col-III protein, and mRNA levels were detected by ELISA and RT-qPCR, respectively, in each group. Moreover, the activation of pS6 in each group was evaluated by Western blot analysis.
2.6. RT-qPCR Analysis
IGF-1, col-I, and col-III mRNA was measured by RT-qPCR in each group. First, we extracted total RNA from LFCs and detected its concentration and purity. Reverse transcription was then performed followed by qPCR. The primer sequences used in the present study are listed in Table 1 [21]. Sangon Biotech (Sangon Biotech, China) synthesized all primers in the study. All assays in the study were performed in triplicate. The samples were normalized to GAPDH and analyzed by the 2-ΔΔCq method [26].
Table 1.
Primers used in the study.
Gene
Sequence (5 ′ to 3 ′)
IGF-1
Forward GTG TTG CTT CCG GAG CTG TG
Reverse CAA ATG TAC TTC CTT CTG AGT C
Collagen I
Forward GTC GAG GGC CAA GAC GAA G
Reverse CAG ATC ACG TCA TCG CAC AAC
Collagen III
Forward ATG TTC CAC GGA AAC ACT GG
Reverse GGA GAG AAG TCG AAG GAA TGC
GAPDH
Forward ACA CCC ACT CCT CCA CCT TT
Reverse TTA CTC CTT GGA GGC CAT GT
2.7. Enzyme-Linked Immunosorbent Assay
Culture supernatants from LFCs in each group were collected. To remove insoluble impurities and cell debris, the supernatants were centrifuged at 1000 g at 4°C for 20 min. The cleared supernatants were immediately used to measure IGF-1, col-I, and col-III protein levels by a Human IGF-1 ELISA Kit (Elabscience Biotechnology, China), Collagen I ELISA Kit (Elabscience Biotechnology, China), and Collagen III ELISA Kit (Elabscience Biotechnology), respectively.
2.8. Western Blot Assays
LFCs from each group were lysed on ice in lysis buffer, and the lysates were then added to Laemmli buffer at 100°C for 10 min. The LFC lysates were separated by electrophoresis, and the proteins were then transferred to nitrocellulose membranes. The membranes were blocked with TBS containing 5% nonfat milk for 2 h at 25°C. Subsequently, the membranes were incubated with primary antibodies for 12 h at 4°C followed by incubation with secondary antibodies for 1.5 h at 25°C. Finally, a chemiluminescence kit (Beyotime, China) was used to visualize the nitrocellulose membranes.
2.9. Statistical Analyses
Data were statistically analyzed and graphed using GraphPad Prism 5.01 (GraphPad Software Inc., San Diego, CA, USA). Protein and mRNA changes with or without mechanical stress at different times were analyzed by one-way ANOVA, and Tukey’ s honestly significant difference was used as the post hoc method. The remaining data were analyzed by Student’s t-test. The results were considered significant when P < 0.05, and the data are presented as the mean ± SD.
3. Results
3.1. Identification and Morphology of LFCs with or without Mechanical Stress
Immunofluorescence staining showed that LFCs expressed high levels of col-I and vimentin (Figure 1), which indicated that highly purified LFCs were cultured. Without mechanical stress, most LFCs were polygonal (Figure 2(a)). Under mechanical stress, LFCs became fusiform and arranged along the direction of stress (Figure 2(b)).
Identification of LFCs. Collagen I (a) and vimentin (d) immunofluorescence staining. Immunofluorescence is shown in green (a, d), and DAPI-stained nuclei are shown in blue (b, e). Merged pictures are shown (c, f). LFCs: ligamentum flavum cells; DAPI: 4 ′,6-diamidino-2-phenylindole. Scale bar = 50 μm.
Identification of LFCs. Collagen I (a) and vimentin (d) immunofluorescence staining. Immunofluorescence is shown in green (a, d), and DAPI-stained nuclei are shown in blue (b, e). Merged pictures are shown (c, f). LFCs: ligamentum flavum cells; DAPI: 4 ′,6-diamidino-2-phenylindole. Scale bar = 50 μm.
Identification of LFCs. Collagen I (a) and vimentin (d) immunofluorescence staining. Immunofluorescence is shown in green (a, d), and DAPI-stained nuclei are shown in blue (b, e). Merged pictures are shown (c, f). LFCs: ligamentum flavum cells; DAPI: 4 ′,6-diamidino-2-phenylindole. Scale bar = 50 μm.
Identification of LFCs. Collagen I (a) and vimentin (d) immunofluorescence staining. Immunofluorescence is shown in green (a, d), and DAPI-stained nuclei are shown in blue (b, e). Merged pictures are shown (c, f). LFCs: ligamentum flavum cells; DAPI: 4 ′,6-diamidino-2-phenylindole. Scale bar = 50 μm.
Identification of LFCs. Collagen I (a) and vimentin (d) immunofluorescence staining. Immunofluorescence is shown in green (a, d), and DAPI-stained nuclei are shown in blue (b, e). Merged pictures are shown (c, f). LFCs: ligamentum flavum cells; DAPI: 4 ′,6-diamidino-2-phenylindole. Scale bar = 50 μm.
Identification of LFCs. Collagen I (a) and vimentin (d) immunofluorescence staining. Immunofluorescence is shown in green (a, d), and DAPI-stained nuclei are shown in blue (b, e). Merged pictures are shown (c, f). LFCs: ligamentum flavum cells; DAPI: 4 ′,6-diamidino-2-phenylindole. Scale bar = 50 μm.
Morphology of LFCs with or without mechanical stress. LFCs were cultured without mechanical stress (a). LFCs were subjected to cycles of relaxation for 10 s and 20% elongation for 10 s (b). LFCs: ligamentum flavum cells. Scale bar = 100 μm.
Morphology of LFCs with or without mechanical stress. LFCs were cultured without mechanical stress (a). LFCs were subjected to cycles of relaxation for 10 s and 20% elongation for 10 s (b). LFCs: ligamentum flavum cells. Scale bar = 100 μm.
3.2. Mechanical Stress Promotes IGF-1, col-I, and col-III Protein and mRNA Production as well as Activation of pIGF-1R, pAKT, and pS6
IGF-1, col-I, and col-III mRNA was examined via RT-qPCR in the stress group and the nonstress group at 6 h, 12 h, and 24 h. Mechanical stress upregulated IGF-1, col-I, and col-III mRNA production in a time-dependent manner (Figures 3(e)–3(g)). Moreover, IGF-1, col-I, and col-III protein levels were examined by ELISA at 6 h, 12 h, and 24 h. Mechanical stress increased IGF-1, col-I, and col-III protein production in a time-dependent manner (Figures 3(h)–3(j)). The activation of pIGF-1R, pAKT, and pS6 was evaluated in the stress group and the nonstress group by Western blot analysis at 6 h, 12 h, and 24 h. Mechanical stress increased the activation of pIGF-1R (Figures 3(a) and 3(b)), pAKT (Figures 3(a) and 3(c)), and pS6 (Figures 3(a) and 3(d)) in a time-dependent manner.
IGF-1R/AKT/mTORC1 signaling pathway-related mRNA and protein changes in LFCs with or without mechanical stress. Mechanical stress upregulated the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d), as well as the mRNA levels of IGF-1 (e), col-I (f), and col-III (g) and the protein levels of IGF-1 (h), col-I (i), and col-III (j) in a time-dependent manner. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1R/AKT/mTORC1 signaling pathway-related mRNA and protein changes in LFCs with or without mechanical stress. Mechanical stress upregulated the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d), as well as the mRNA levels of IGF-1 (e), col-I (f), and col-III (g) and the protein levels of IGF-1 (h), col-I (i), and col-III (j) in a time-dependent manner. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1R/AKT/mTORC1 signaling pathway-related mRNA and protein changes in LFCs with or without mechanical stress. Mechanical stress upregulated the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d), as well as the mRNA levels of IGF-1 (e), col-I (f), and col-III (g) and the protein levels of IGF-1 (h), col-I (i), and col-III (j) in a time-dependent manner. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1R/AKT/mTORC1 signaling pathway-related mRNA and protein changes in LFCs with or without mechanical stress. Mechanical stress upregulated the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d), as well as the mRNA levels of IGF-1 (e), col-I (f), and col-III (g) and the protein levels of IGF-1 (h), col-I (i), and col-III (j) in a time-dependent manner. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1R/AKT/mTORC1 signaling pathway-related mRNA and protein changes in LFCs with or without mechanical stress. Mechanical stress upregulated the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d), as well as the mRNA levels of IGF-1 (e), col-I (f), and col-III (g) and the protein levels of IGF-1 (h), col-I (i), and col-III (j) in a time-dependent manner. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1R/AKT/mTORC1 signaling pathway-related mRNA and protein changes in LFCs with or without mechanical stress. Mechanical stress upregulated the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d), as well as the mRNA levels of IGF-1 (e), col-I (f), and col-III (g) and the protein levels of IGF-1 (h), col-I (i), and col-III (j) in a time-dependent manner. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1R/AKT/mTORC1 signaling pathway-related mRNA and protein changes in LFCs with or without mechanical stress. Mechanical stress upregulated the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d), as well as the mRNA levels of IGF-1 (e), col-I (f), and col-III (g) and the protein levels of IGF-1 (h), col-I (i), and col-III (j) in a time-dependent manner. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1R/AKT/mTORC1 signaling pathway-related mRNA and protein changes in LFCs with or without mechanical stress. Mechanical stress upregulated the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d), as well as the mRNA levels of IGF-1 (e), col-I (f), and col-III (g) and the protein levels of IGF-1 (h), col-I (i), and col-III (j) in a time-dependent manner. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1R/AKT/mTORC1 signaling pathway-related mRNA and protein changes in LFCs with or without mechanical stress. Mechanical stress upregulated the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d), as well as the mRNA levels of IGF-1 (e), col-I (f), and col-III (g) and the protein levels of IGF-1 (h), col-I (i), and col-III (j) in a time-dependent manner. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1R/AKT/mTORC1 signaling pathway-related mRNA and protein changes in LFCs with or without mechanical stress. Mechanical stress upregulated the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d), as well as the mRNA levels of IGF-1 (e), col-I (f), and col-III (g) and the protein levels of IGF-1 (h), col-I (i), and col-III (j) in a time-dependent manner. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
3.3. IGF-1 Neutralizing Antibody Reduces col-I and col-III mRNA Production; Reduces IGF-1, col-I, and col-III Protein Production; and Suppresses the Activation of pIGF-1R, pAKT, and pS6
IGF-1, col-I, and col-III mRNA and protein levels were examined by RT-qPCR and ELISA, respectively, at 24 h for the nonstress group, the stress group, and the stress+10 μg/ml IGF-1 neutralizing antibody group. The IGF-1 neutralizing antibody reduced the mRNA levels of col-I/col-III (Figures 4(f) and 4(g)), but not IGF-1 (Figure 4(e)). Moreover, IGF-1, col-I, and col-III protein levels were reduced by the IGF-1 neutralizing antibody (Figures 4(h)–4(j)). Furthermore, IGF-1 neutralizing antibody suppressed the activation of pIGF-1R (Figures 4(a) and 4(b)), pAKT (Figures 4(a) and 4(c)), and pS6 (Figures 4(a) and 4(d)).
IGF-1 neutralizing antibody treatment. Mechanical stress in the nonstress group, the stress group, and the stress+10 μg/ml IGF-1 neutralizing antibody group. The IGF-1 neutralizing antibody reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). The IGF-1 neutralizing antibody also reduced the protein expression of IGF-1 (h), col-I (i), and col-III (j). In addition, the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d) was reduced by the IGF-1 neutralizing antibody. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1 neutralizing antibody treatment. Mechanical stress in the nonstress group, the stress group, and the stress+10 μg/ml IGF-1 neutralizing antibody group. The IGF-1 neutralizing antibody reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). The IGF-1 neutralizing antibody also reduced the protein expression of IGF-1 (h), col-I (i), and col-III (j). In addition, the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d) was reduced by the IGF-1 neutralizing antibody. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1 neutralizing antibody treatment. Mechanical stress in the nonstress group, the stress group, and the stress+10 μg/ml IGF-1 neutralizing antibody group. The IGF-1 neutralizing antibody reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). The IGF-1 neutralizing antibody also reduced the protein expression of IGF-1 (h), col-I (i), and col-III (j). In addition, the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d) was reduced by the IGF-1 neutralizing antibody. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1 neutralizing antibody treatment. Mechanical stress in the nonstress group, the stress group, and the stress+10 μg/ml IGF-1 neutralizing antibody group. The IGF-1 neutralizing antibody reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). The IGF-1 neutralizing antibody also reduced the protein expression of IGF-1 (h), col-I (i), and col-III (j). In addition, the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d) was reduced by the IGF-1 neutralizing antibody. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1 neutralizing antibody treatment. Mechanical stress in the nonstress group, the stress group, and the stress+10 μg/ml IGF-1 neutralizing antibody group. The IGF-1 neutralizing antibody reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). The IGF-1 neutralizing antibody also reduced the protein expression of IGF-1 (h), col-I (i), and col-III (j). In addition, the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d) was reduced by the IGF-1 neutralizing antibody. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1 neutralizing antibody treatment. Mechanical stress in the nonstress group, the stress group, and the stress+10 μg/ml IGF-1 neutralizing antibody group. The IGF-1 neutralizing antibody reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). The IGF-1 neutralizing antibody also reduced the protein expression of IGF-1 (h), col-I (i), and col-III (j). In addition, the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d) was reduced by the IGF-1 neutralizing antibody. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1 neutralizing antibody treatment. Mechanical stress in the nonstress group, the stress group, and the stress+10 μg/ml IGF-1 neutralizing antibody group. The IGF-1 neutralizing antibody reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). The IGF-1 neutralizing antibody also reduced the protein expression of IGF-1 (h), col-I (i), and col-III (j). In addition, the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d) was reduced by the IGF-1 neutralizing antibody. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1 neutralizing antibody treatment. Mechanical stress in the nonstress group, the stress group, and the stress+10 μg/ml IGF-1 neutralizing antibody group. The IGF-1 neutralizing antibody reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). The IGF-1 neutralizing antibody also reduced the protein expression of IGF-1 (h), col-I (i), and col-III (j). In addition, the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d) was reduced by the IGF-1 neutralizing antibody. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1 neutralizing antibody treatment. Mechanical stress in the nonstress group, the stress group, and the stress+10 μg/ml IGF-1 neutralizing antibody group. The IGF-1 neutralizing antibody reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). The IGF-1 neutralizing antibody also reduced the protein expression of IGF-1 (h), col-I (i), and col-III (j). In addition, the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d) was reduced by the IGF-1 neutralizing antibody. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
IGF-1 neutralizing antibody treatment. Mechanical stress in the nonstress group, the stress group, and the stress+10 μg/ml IGF-1 neutralizing antibody group. The IGF-1 neutralizing antibody reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). The IGF-1 neutralizing antibody also reduced the protein expression of IGF-1 (h), col-I (i), and col-III (j). In addition, the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d) was reduced by the IGF-1 neutralizing antibody. Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
3.4. NVP-AEW541 Reduces IGF-1, col-I, and col-III Protein and mRNA Production and Suppresses the Activation of pIGF-1R, pAKT, and pS6
IGF-1, col-I, and col-III mRNA and protein levels were examined by RT-qPCR and ELISA, respectively, at 24 h in the nonstress group, the stress group, and the stress+100 ng/ml NVP-AEW541 group. NVP-AEW541 reduced the mRNA levels of col-I/col-III mRNA (Figures 5(f) and 5(g)), but not IGF-1 (Figure 5(e)), and it reduced the protein levels of col-I/col-III protein (Figures 5(i) and 5(j)), but not IGF-1 (Figure 5(h)). In addition, the activation of pIGF-1R (Figures 5(a) and 5(b)), pAKT (Figures 5(a) and 5(c)), and pS6 (Figures 5(a) and 5(d)) was reduced by NVP-AEW541.
NVP-AEW541 treatment. Mechanical stress in the nonstress group, the stress group, and the stress+100 ng/ml NVP-AEW541 group. NVP-AEW541 reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). col-I (i) and col-III (j) protein levels, but not IGF-1 (h) protein levels, were attenuated by NVP-AEW541. In addition, NVP-AEW541 reduced the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
NVP-AEW541 treatment. Mechanical stress in the nonstress group, the stress group, and the stress+100 ng/ml NVP-AEW541 group. NVP-AEW541 reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). col-I (i) and col-III (j) protein levels, but not IGF-1 (h) protein levels, were attenuated by NVP-AEW541. In addition, NVP-AEW541 reduced the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
NVP-AEW541 treatment. Mechanical stress in the nonstress group, the stress group, and the stress+100 ng/ml NVP-AEW541 group. NVP-AEW541 reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). col-I (i) and col-III (j) protein levels, but not IGF-1 (h) protein levels, were attenuated by NVP-AEW541. In addition, NVP-AEW541 reduced the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
NVP-AEW541 treatment. Mechanical stress in the nonstress group, the stress group, and the stress+100 ng/ml NVP-AEW541 group. NVP-AEW541 reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). col-I (i) and col-III (j) protein levels, but not IGF-1 (h) protein levels, were attenuated by NVP-AEW541. In addition, NVP-AEW541 reduced the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
NVP-AEW541 treatment. Mechanical stress in the nonstress group, the stress group, and the stress+100 ng/ml NVP-AEW541 group. NVP-AEW541 reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). col-I (i) and col-III (j) protein levels, but not IGF-1 (h) protein levels, were attenuated by NVP-AEW541. In addition, NVP-AEW541 reduced the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
NVP-AEW541 treatment. Mechanical stress in the nonstress group, the stress group, and the stress+100 ng/ml NVP-AEW541 group. NVP-AEW541 reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). col-I (i) and col-III (j) protein levels, but not IGF-1 (h) protein levels, were attenuated by NVP-AEW541. In addition, NVP-AEW541 reduced the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
NVP-AEW541 treatment. Mechanical stress in the nonstress group, the stress group, and the stress+100 ng/ml NVP-AEW541 group. NVP-AEW541 reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). col-I (i) and col-III (j) protein levels, but not IGF-1 (h) protein levels, were attenuated by NVP-AEW541. In addition, NVP-AEW541 reduced the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
NVP-AEW541 treatment. Mechanical stress in the nonstress group, the stress group, and the stress+100 ng/ml NVP-AEW541 group. NVP-AEW541 reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). col-I (i) and col-III (j) protein levels, but not IGF-1 (h) protein levels, were attenuated by NVP-AEW541. In addition, NVP-AEW541 reduced the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
NVP-AEW541 treatment. Mechanical stress in the nonstress group, the stress group, and the stress+100 ng/ml NVP-AEW541 group. NVP-AEW541 reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). col-I (i) and col-III (j) protein levels, but not IGF-1 (h) protein levels, were attenuated by NVP-AEW541. In addition, NVP-AEW541 reduced the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
NVP-AEW541 treatment. Mechanical stress in the nonstress group, the stress group, and the stress+100 ng/ml NVP-AEW541 group. NVP-AEW541 reduced the mRNA levels of col-I (f) and col-III (g), but not IGF-1 (e). col-I (i) and col-III (j) protein levels, but not IGF-1 (h) protein levels, were attenuated by NVP-AEW541. In addition, NVP-AEW541 reduced the activation of pIGF-1R (a, b), pAKT (a, c), and pS6 (a, d). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
3.5. Rapamycin Reduces IGF-1, col-I, and col-III Protein and mRNA Production and Suppresses the Activation of pS6
IGF-1, col-I, and col-III mRNA and protein levels were detected by RT-qPCR and ELISA, respectively, at 24 h in the nonstress group, the stress group, and the stress+10 ng/ml rapamycin group. Rapamycin decreased the mRNA levels of col-I/col-III (Figures 6(d) and 6(e)), but not IGF-1 (Figure 6(c)), and it reduced the protein levels of col-I/col-III (Figures 6(g) and 6(h)), but not IGF-1 (Figure 6(f)). In addition, the induction of pS6 was suppressed by rapamycin (Figures 6(a) and 6(b)).
Rapamycin treatment. Mechanical stress in the nonstress group, the stress group, and the stress+rapamycin group. Rapamycin reduced the mRNA levels of col-I (d) and col-III (e), but not IGF-1 (c). Rapamycin reduced the protein levels of col-I (g) and col-III (h), but not IGF-1 (f). In addition, rapamycin reduced the activation of pS6 (a, b). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
Rapamycin treatment. Mechanical stress in the nonstress group, the stress group, and the stress+rapamycin group. Rapamycin reduced the mRNA levels of col-I (d) and col-III (e), but not IGF-1 (c). Rapamycin reduced the protein levels of col-I (g) and col-III (h), but not IGF-1 (f). In addition, rapamycin reduced the activation of pS6 (a, b). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
Rapamycin treatment. Mechanical stress in the nonstress group, the stress group, and the stress+rapamycin group. Rapamycin reduced the mRNA levels of col-I (d) and col-III (e), but not IGF-1 (c). Rapamycin reduced the protein levels of col-I (g) and col-III (h), but not IGF-1 (f). In addition, rapamycin reduced the activation of pS6 (a, b). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
Rapamycin treatment. Mechanical stress in the nonstress group, the stress group, and the stress+rapamycin group. Rapamycin reduced the mRNA levels of col-I (d) and col-III (e), but not IGF-1 (c). Rapamycin reduced the protein levels of col-I (g) and col-III (h), but not IGF-1 (f). In addition, rapamycin reduced the activation of pS6 (a, b). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
Rapamycin treatment. Mechanical stress in the nonstress group, the stress group, and the stress+rapamycin group. Rapamycin reduced the mRNA levels of col-I (d) and col-III (e), but not IGF-1 (c). Rapamycin reduced the protein levels of col-I (g) and col-III (h), but not IGF-1 (f). In addition, rapamycin reduced the activation of pS6 (a, b). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
Rapamycin treatment. Mechanical stress in the nonstress group, the stress group, and the stress+rapamycin group. Rapamycin reduced the mRNA levels of col-I (d) and col-III (e), but not IGF-1 (c). Rapamycin reduced the protein levels of col-I (g) and col-III (h), but not IGF-1 (f). In addition, rapamycin reduced the activation of pS6 (a, b). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
Rapamycin treatment. Mechanical stress in the nonstress group, the stress group, and the stress+rapamycin group. Rapamycin reduced the mRNA levels of col-I (d) and col-III (e), but not IGF-1 (c). Rapamycin reduced the protein levels of col-I (g) and col-III (h), but not IGF-1 (f). In addition, rapamycin reduced the activation of pS6 (a, b). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
Rapamycin treatment. Mechanical stress in the nonstress group, the stress group, and the stress+rapamycin group. Rapamycin reduced the mRNA levels of col-I (d) and col-III (e), but not IGF-1 (c). Rapamycin reduced the protein levels of col-I (g) and col-III (h), but not IGF-1 (f). In addition, rapamycin reduced the activation of pS6 (a, b). Columns represent the mean ± SD of 3 samples, and each experiment was performed in triplicate. LFCs: ligamentum flavum cells; IGF-1: insulin-like growth factor 1; col-I: collagen I; col-III: collagen III. “∗” represents P < 0.05; “ns” indicates P > 0.05.
4. Discussion
In previous studies, LFH has been identified as a common cause of LSS [3–5]. LFH is caused by increased collagen levels, mainly col-I and col-III [8, 21, 27–29]. Many inflammatory and growth factors such as IL-1, IL-6, TGF-β1, VEGF, PDGF-BB, CTGF, and TNF-α have been reported to promote col-I and col-III production, eventually leading to LFH [8, 21, 27, 30–36]. Chuang et al. [37] showed that oxidative stress activates the Akt and MAPK pathways to upregulate inflammatory mediator (iNOS and NF-κB) and fibrotic marker (TGF-β, β-catenin, α-SMA, and vimentin) expression levels, thereby contributing to LFH. Habibi et al. [38] confirmed that acidic fibroblast growth factor (FGF-1) expression is higher in LSS patient tissues than in nonhypertrophied ligamentum flavum tissues.
IGF-1 is a vital growth factor that promotes collagen production via the mTORC1 signaling pathway [11–13]. According to previous studies [14–17], IGF-1 is released by various types of cells under mechanical stress and IGF-1 increases collagen expression levels, which contributes to the hypertrophy of various tissues. Some studies have also reported [6–9] that mechanical stress may play a vital role in LFH. Nakatani et al. [8] indicated that mechanical stress stimulates LFCs to produce TGF-βl, which increases the synthesis of collagens, resulting in LFH. Hayashi et al. [9] reported that fibroblast growth factor 9 (FGF9) and its pathway contribute to LFH under mechanical stress. Reijnders et al. [18] reported that mechanical stress results in IGF-1 mRNA upregulation in osteocytes of rat tibia and that IGF-1 is involved in the translation of mechanical stress to bone formation. Juffer et al. [19] showed that mechanical stress stimulates MLO-Y4 osteocytes to express IGF-1 isoform, which is an important factor in anabolism and metabolism in muscle, at the mRNA and protein levels. However, the interaction between mechanical stress and IGF-1 has not been previously studied in LFH. In the present study, we researched the correlation of mechanical stress, IGF-1, and the IGF-1R/AKT/mTORC1 signaling pathway in LFH.
First, we isolated primary LFCs from 9 patients who underwent lumbar spinal surgery. LFCs are fibrous connective tissue stem cells. According to the study conducted by Zhong and Chen [39], LFCs can be identified by detecting col-I and vimentin expression. Therefore, in the present study, LFC purity was examined by col-I and vimentin expression. Immunofluorescence results showed that the LFCs were of high purity (Figure 1). In addition, LFC viability was evaluated by the MTT assay (Solarbio, China), which demonstrated that there were no changes in LFC viability in each group.
LFCs were also subjected to cyclic mechanical stress at different times. Compared to nonstressed cells, cyclic mechanical stress promoted the synthesis of IGF-1 in LFCs in a time-dependent manner, which eventually led to col-I/col-III accumulation via the IGF-1R/AKT/mTORC1 signaling pathway. To understand the molecular mechanism involved, we used an IGF-1 neutralizing antibody. Compared to the nonstress group, IGF-1, col-I, and col-III protein and mRNA levels were increased in the stress group. In addition, col-I and col-III protein and mRNA levels were significantly reduced in the stress+IGF-1 neutralizing antibody group compared to the stress group. Interestingly, IGF-1 protein expression, but not mRNA expression, was reduced in the stress+IGF-1 neutralizing antibody group compared to the stress group. Correspondingly, the activation of pIGF-1R, pAKT, and pS6 was decreased in the stress+IGF-1 neutralizing antibody group compared to the stress group. For further investigation, NVP-AEW541 (a specific inhibitor of IGF-1R) and rapamycin (a specific inhibitor of mTORC1) were used in the present study. Although 100 ng/ml NVP-AEW541 and 10 ng/ml rapamycin almost completely blocked the IGF-1R/AKT/mTORC1 signaling pathway, col-I and col-III protein and mRNA levels were only partially reduced. col-I and col-III protein and mRNA levels were still higher in both groups compared to the nonstress group. Moreover, neither NVP-AEW541 nor rapamycin reversed IGF-1 expression, which was induced by mechanical stress.
Based on the above findings, we hypothesized that mechanical stress may promote col-I and col-III production via other signaling pathways, and the potential mechanism involved requires further study. In addition, due to the lack of an animal model of LFH, only cytological experiments were performed in the present study. Thus, it is necessary to build an effective animal model for further research.
5. Conclusion
In summary, the present study showed that mechanical stress upregulated IGF-1, col-I, and col-III protein and mRNA production. The IGF-1 neutralizing antibody, NVP-AEW541, and rapamycin blocked the IGF-1R/AKT/mTORC1 signaling pathway and reduced col-I and col-III production in LFCs. These findings demonstrated that cyclic mechanical stress promotes LFCs to secrete IGF-1, which induces col-I and col-III synthesis via the IGF-1R/AKT/mTORC1 signaling pathway (Figure 7). These results provide a new understanding of LFH and may facilitate the development of novel methods to treat LSS.
Potential mechanism by which mechanical stress promotes collagen I and collagen III synthesis.
Conflicts of Interest
The authors in the study declare that they have no conflicts of interest.
Authors’ Contributions
Bin Yan, Canjun Zeng, and Yuhui Chen contributed equally to this work.
Acknowledgments
The National Natural Science Foundation of China (No. 31801012) and Science and Technology Program of Guangzhou, China (201804010390), supported this study.
2Yabe Y.,
Hagiwara Y.,
Tsuchiya M.,
Honda M.,
Hatori K.,
Sonofuchi K.,
Kanazawa K.,
Koide M.,
Sekiguchi T.,
Itaya N., and
Itoi E., Decreased elastic fibers and increased proteoglycans in the ligamentum flavum of patients with lumbar spinal canal stenosis, Journal of Orthopaedic Research. (2016) 34, no. 7, 1241–1247, https://doi.org/10.1002/jor.23130, 2-s2.0-84978540608, 26679090.
3Jatteau P. and
Bardonnet A., Pathomechanism of ligamentum flavum hypertrophy: a multidisciplinary investigation based on clinical, biomechanical, histologic, and biologic assessments, Spine. (2005) 30, no. 23.
6Okuda T.,
Baba I.,
Fujimoto Y.,
Tanaka N.,
Sumida T.,
Manabe H.,
Hayashi Y., and
Ochi M., The pathology of ligamentum flavum in degenerative lumbar disease, Spine. (2004) 29, no. 15, 1689–1697, https://doi.org/10.1097/01.BRS.0000132510.25378.8C, 2-s2.0-3542998653, 15284518.
7Hur J. W.,
Kim B. J.,
Park J. H.,
Kim J. H.,
Park Y. K.,
Kwon T. H., and
Moon H. J., The mechanism of ligamentum flavum hypertrophy, Neurosurgery. (2015) 77, no. 2, 274–282, https://doi.org/10.1227/NEU.0000000000000755, 2-s2.0-84937406767, 25850600.
8Nakatani T.,
Marui T.,
Hitora T.,
Doita M.,
Nishida K., and
Kurosaka M., Mechanical stretching force promotes collagen synthesis by cultured cells from human ligamentum flavum via transforming growth factor-beta1, Journal of Orthopaedic Research. (2002) 20, no. 6, 1380–1386, https://doi.org/10.1016/S0736-0266(02)00046-3, 2-s2.0-0036436022, 12472256.
9Hayashi K.,
Suzuki A.,
Terai H.,
Ahmadi S. A.,
Rahmani M. S.,
Maruf M. H.,
Habibi H.,
Hori Y.,
Yamada K.,
Hoshino M.,
Toyoda H.,
Takahashi S.,
Tamai K.,
Ohyama S.,
Imai Y., and
Nakamura H., Fibroblast growth factor 9 is upregulated upon intervertebral mechanical stress-induced ligamentum flavum hypertrophy in a rabbit model, Spine. (2019) 44, no. 20, E1172–E1180, https://doi.org/10.1097/BRS.0000000000003089, 2-s2.0-85072848853, 31022154.
10Zhang Z.,
Li L.,
Yang W.,
Cao Y.,
Shi Y.,
Li X., and
Zhang Q., The effects of different doses of IGF-1 on cartilage and subchondral bone during the repair of full-thickness articular cartilage defects in rabbits, Osteoarthritis and Cartilage. (2017) 25, no. 2, 309–320, https://doi.org/10.1016/j.joca.2016.09.010, 2-s2.0-85000613485, 27662821.
11Bakker A. D.,
Gakes T.,
Hogervorst J. M. A.,
de Wit G. M. J.,
Klein-Nulend J., and
Jaspers R. T., Mechanical stimulation and IGF-1 enhance mRNA translation rate in osteoblasts via activation of the AKT-mTOR pathway, Journal of Cellular Physiology. (2016) 231, no. 6, 1283–1290, https://doi.org/10.1002/jcp.25228, 2-s2.0-84958122112, 26505782.
12Ding M.,
Bruick R. K., and
Yu Y., Secreted IGFBP5 mediates mTORC1-dependent feedback inhibition of IGF-1 signalling, Nature Cell Biology. (2016) 18, no. 3, 319–327.
13Xian L.,
Wu X.,
Pang L.,
Lou M.,
Rosen C. J.,
Qiu T.,
Crane J.,
Frassica F.,
Zhang L.,
Rodriguez J. P.,
Jia X.,
Yakar S.,
Xuan S.,
Efstratiadis A.,
Wan M., and
Cao X., Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells, Nature Medicine. (2012) 18, no. 7, 1095–1101, https://doi.org/10.1038/nm.2793, 2-s2.0-84863726841, 22729283.
14Blackstock C. D.,
Higashi Y.,
Sukhanov S.,
Shai S. Y.,
Stefanovic B.,
Tabony A. M.,
Yoshida T., and
Delafontaine P., Insulin-like Growth Factor-1 Increases Synthesis of Collagen Type I via Induction of the mRNA-binding Protein LARP6 Expression and Binding to the 5 ′ Stem-loop of COL1a1 and COL1a2 mRNA∗, Journal of Biological Chemistry. (2014) 289, no. 11, 7264–7274, https://doi.org/10.1074/jbc.M113.518951, 2-s2.0-84896302141, 24469459.
15Doessing S.,
Holm L.,
Heinemeier K. M.,
Feldt-Rasmussen U.,
Schjerling P.,
Qvortrup K.,
Larsen J. O.,
Nielsen R. H.,
Flyvbjerg A., and
Kjaer M., GH and IGF1 levels are positively associated with musculotendinous collagen expression: experiments in acromegalic and GH deficiency patients, European Journal of Endocrinology. (2010) 163, no. 6, 853–862, https://doi.org/10.1530/EJE-10-0818, 2-s2.0-78649814515, 20858702.
16Li P., Resveratrol inhibits collagen I synthesis by suppressing IGF-1R activation in intestinal fibroblasts, World Journal of Gastroenterology. (2014) 20, no. 16.
17Honsho S.,
Nishikawa S.,
Amano K.,
Zen K.,
Adachi Y.,
Kishita E.,
Matsui A.,
Katsume A.,
Yamaguchi S.,
Nishikawa K.,
Isoda K.,
Riches D. W. H.,
Matoba S.,
Okigaki M., and
Matsubara H., Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways, Circulation Research. (2009) 105, no. 11, 1149–1158, https://doi.org/10.1161/CIRCRESAHA.109.208199, 2-s2.0-73349089976, 19834007.
18Reijnders C. M. A.,
Bravenboer N.,
Tromp A. M.,
Blankenstein M. A., and
Lips P., Effect of mechanical loading on insulin-like growth factor-I gene expression in rat tibia, Journal of Endocrinology. (2007) 192, no. 1, 131–140, https://doi.org/10.1677/joe.1.06880, 2-s2.0-33947377168.
19Juffer P.,
Jaspers R. T.,
Lips P.,
Bakker A. D., and
Klein-Nulend J., Expression of muscle anabolic and metabolic factors in mechanically loaded MLO-Y4 osteocytes, American Journal of Physiology. Endocrinology and Metabolism. (2012) 302, no. 4, E389–E395, https://doi.org/10.1152/ajpendo.00320.2011, 2-s2.0-84856602560, 22114022.
20Yan B.,
Huang M.,
Zeng C.,
Yao N.,
Zhang J.,
Yan B.,
Jiang H.,
Tian X.,
Ao X.,
Zhao H.,
Zhou W.,
Chu J.,
Wang L.,
Xian C. J.,
Zhang Z., and
Wang L., Locally produced IGF-1 promotes hypertrophy of the ligamentum flavum via the mTORC1 signaling pathway, Cellular Physiology and Biochemistry. (2018) 48, no. 1, 293–303, https://doi.org/10.1159/000491729, 2-s2.0-85052322827, 30016763.
21Zhong Z.-M.,
Zha D. S.,
Xiao W. D.,
Wu S. H.,
Wu Q.,
Zhang Y.,
Liu F. Q., and
Chen J. T., Hypertrophy of ligamentum flavum in lumbar spine stenosis associated with the increased expression of connective tissue growth factor, Journal of Orthopaedic Research. (2011) 29, no. 10, 1592–1597, https://doi.org/10.1002/jor.21431, 2-s2.0-80051549814, 21484860.
22Iwasaki K.,
Furukawa K. I.,
Tanno M.,
Kusumi T.,
Ueyama K.,
Tanaka M.,
Kudo H.,
Toh S.,
Harata S., and
Motomura S., Uni-axial cyclic stretch induces Cbfa1 expression in spinal ligament cells derived from patients with ossification of the posterior longitudinal ligament, Calcified Tissue International. (2004) 74, no. 5, 448–457, https://doi.org/10.1007/s00223-002-0021-1, 2-s2.0-2442448710, 14639470.
23Ohishi H. et al., Role of prostaglandin Iin the gene expression induced by mechanical stress in spinal ligament cells derived from patients with ossification of the posterior longitudinal ligament, Journal of Neurology Neurosurgery & Psychiatry. (2003) 86, no. 10, 1082–1088.
25Cai H. X.,
Yayama T.,
Uchida K.,
Nakajima H.,
Sugita D.,
Guerrero A. R.,
Yoshida A., and
Baba H., Cyclic tensile strain facilitates the ossification of ligamentum flavum through β-catenin signaling pathway: in vitro analysis, Spine. (2012) 37, no. 11, E639–E646, https://doi.org/10.1097/BRS.0b013e318242a132, 2-s2.0-84861101657, 22158061.
26Livak K. J. and
Schmittgen T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method, Methods. (2001) 25, no. 4, 402–408.
27Zhang Y.,
Chen J.,
Zhong Z. M.,
Yang D., and
Zhu Q., Is platelet-derived growth factor-BB expression proportional to fibrosis in the hypertrophied lumber ligamentum flavum?, Spine. (2010) 35, no. 25, E1479–E1486, https://doi.org/10.1097/BRS.0b013e3181f3d2df, 21102276.
28Kosaka H.,
Sairyo K.,
Biyani A.,
Leaman D.,
Yeasting R.,
Higashino K.,
Sakai T.,
Katoh S.,
Sano T.,
Goel V. K., and
Yasui N., Pathomechanism of loss of elasticity and hypertrophy of lumbar ligamentum flavum in elderly patients with lumbar spinal canal stenosis, Spine. (2007) 32, no. 25, 2805–2811, https://doi.org/10.1097/BRS.0b013e31815b650f, 2-s2.0-39049089534, 18246001.
29Yabe Y.,
Hagiwara Y.,
Ando A.,
Tsuchiya M.,
Minowa T.,
Takemura T.,
Honda M.,
Hatori K.,
Sonofuchi K.,
Kanazawa K.,
Koide M.,
Sekiguchi T., and
Itoi E., Chondrogenic and fibrotic process in the ligamentum flavum of patients with lumbar spinal canal stenosis, Spine. (2015) 40, no. 7, 429–435, https://doi.org/10.1097/BRS.0000000000000795, 2-s2.0-84958105556, 25627290.
30Sairyo K.,
Biyani A.,
Goel V. K.,
Leaman D. W.,
BoothR.Jr., Thomas J.,
Ebraheim N. A.,
Cowgill I. A., and
Mohan S. E., Lumbar ligamentum flavum hypertrophy is due to accumulation of inflammation-related scar tissue, Spine. (2007) 32, no. 11, E340–E347, https://doi.org/10.1097/01.brs.0000263407.25009.6e, 2-s2.0-34248332147.
31Park J. O.,
Lee B. H.,
Kang Y. M.,
Kim T. H.,
Yoon J. Y.,
Kim H.,
Kwon U. H.,
Lee K. I.,
Lee H. M., and
Moon S. H., Inflammatory cytokines induce fibrosis and ossification of human ligamentum flavum cells, Journal of Spinal Disorders & Techniques. (2013) 26, no. 1, E6–E12, https://doi.org/10.1097/BSD.0b013e3182698501, 2-s2.0-84873406336, 22832553.
32Kim B. J.,
Hur J. W.,
Park J. S.,
Kim J. H.,
Kwon T. H.,
Park Y. K., and
Moon H. J., Expression of matrix metalloproteinase-2 and -9 in human ligamentum flavum cells treated with tumor necrosis factor-α and interleukin-1β, Journal of Neurosurgery Spine. (2016) 24, no. 3, 428–435, https://doi.org/10.3171/2015.6.SPINE141271, 2-s2.0-84982171363, 26565765.
33Lakemeier S.,
Schofer M. D.,
Foltz L.,
Schmid R.,
Efe T.,
Rohlfs J.,
Fuchs-Winkelmann S.,
el-Zayat B. F.,
Paletta J. R. J., and
Foelsch C., Expression of hypoxia-inducible Factor-1α, vascular endothelial growth factor, and matrix metalloproteinases 1, 3, and 9 in hypertrophied ligamentum flavum, Journal of Spinal Disorders & Techniques. (2013) 26, no. 7, 400–406, https://doi.org/10.1097/BSD.0b013e3182495b88, 2-s2.0-84885485927, 22323068.
34Löhr M.,
Hampl J. A.,
Lee J. Y.,
Ernestus R. I.,
Deckert M., and
Stenzel W., Hypertrophy of the lumbar ligamentum flavum is associated with inflammation-related TGF-β expression, Acta Neurochirurgica. (2011) 153, no. 1, 134–141, https://doi.org/10.1007/s00701-010-0839-7, 2-s2.0-78651250107, 20960015.
35Cao Y. L.,
Duan Y.,
Zhu L. X.,
Zhan Y. N.,
Min S. X., and
Jin A. M., TGF-β1, in association with the increased expression of connective tissue growth factor, induce the hypertrophy of the ligamentum flavum through the p38 MAPK pathway, International Journal of Molecular Medicine. (2016) 38, no. 2, 391–398, https://doi.org/10.3892/ijmm.2016.2631, 2-s2.0-84978922956, 27279555.
36Hur J. W.,
Bae T.,
Ye S.,
Kim J. H.,
Lee S.,
Kim K.,
Lee S. H.,
Kim J. S.,
Lee J. B.,
Cho T. H., and
Park J. Y., Myofibroblast in the ligamentum flavum hypertrophic activity, European Spine Journal. (2017) 26, 1–10.
37Chuang H. C.,
Tsai K. L.,
Tsai K. J.,
Tu T. Y.,
Shyong Y. J.,
Jou I. M.,
Hsu C. C.,
Shih S. S.,
Liu Y. F., and
Lin C. L., Oxidative stress mediates age-related hypertrophy of ligamentum flavum by inducing inflammation, fibrosis, and apoptosis through activating Akt and MAPK pathways, Aging. (2020) 12, no. 23, 24168–24183, https://doi.org/10.18632/aging.104105, 33223505.
38Habibi H.,
Suzuki A.,
Hayashi K.,
Salimi H.,
Hori Y.,
Orita K.,
Yabu A.,
Terai H., and
Nakamura H., Expression and function of fibroblast growth factor 1 in the hypertrophied ligamentum flavum of lumbar spinal stenosis, Journal of Orthopaedic Science. (2021) S0949-2658, no. 21, article id 00037-3, https://doi.org/10.1016/j.jos.2021.01.004, 33637374.
39Zhong Z. M. and
Chen J. T., Phenotypic characterization of ligamentum flavum cells from patients with ossification of ligamentum flavum, Yonsei Medical Journal. (2009) 50, no. 3, 375–379.
Please check your email for instructions on resetting your password.
If you do not receive an email within 10 minutes, your email address may not be registered,
and you may need to create a new Wiley Online Library account.
Request Username
Can't sign in? Forgot your username?
Enter your email address below and we will send you your username
If the address matches an existing account you will receive an email with instructions to retrieve your username
The full text of this article hosted at iucr.org is unavailable due to technical difficulties.
